Rulonilimab is under clinical development by Shandong New Time Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rulonilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
F-520 is under development for the treatment of advanced solid tumors, transitional cell carcinoma (urothelial cell carcinoma), cervical cancer, urethral cancer, bladder cancer and ureter cancer, relapsed and refractory peripheral T cell lymphoma (PTCL), endometrial cancer, squamous and non- squamous non-small cell lung cancer, hepatocellular carcinoma and relapsed/refractory primary testicular diffuse large B-cell lymphoma. The drug candidate is a recombinant humanized monoclonal antibody. It is administered by administered as intravenous drip. The drug candidate acts by targeting programmed cell death protein 1 (PD1).
It was also under development for the treatment of relapsed and refractory primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL)
For a complete picture of Rulonilimab’s drug-specific PTSR and LoA scores, buy the report here.